Business
Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologiesRA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagn
About this update from Qtrex Quantum Ltd.
[{"type":"image","alt":"Inspira Technologies","displaySize":"","headline":null,"caption":"Inspira Technologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Fe6OoV8FaU0yBPMg3F6WQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f3cd7fe01a01b6d2fcb4b07615d7a878","width":300,"height":71}},"lazy":false},{"type":"text","content":"Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologies","length":153,"tagName":"p"},{"type":"text","content":"RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company’s core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the “Equity Investment”), positioning Inspira to pursue long-term growth while protecting and monetizing the value of its existing business.","length":840,"tagName":"p"},{"type":"text","content":"Tal Parnes, Chairman of the Board of Inspira Technologies, stated: “The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a high-impact diagnostics capability with substantial long-term potential. The Board and management have deliberately structured this transaction to pursue this growth opportunity while optimally allocating value between the new platform and Inspira’s core respiratory business through a CVR framework. We view this as disciplined, strategic value creation designed to maximize upside across both platforms.”","length":604,"tagName":"p"},{"type":"text","content":"The proposed acquisition represents a natural and execution-ready expansion...